DMT SUIK

Add Drug

Prices & Coupons

133rd st pharmacy inc

1473 Amsterdam Ave
New York ny 10027
(212)491-4911

$193.24

Get Your Coupon

ahf pharmacy

475 Atlantic Ave
Brooklyn ny 11217
(718)637-2970

$193.24

Get Your Coupon 2 more results found for aids healthcare foundation

alice rx corp

231 S 3rd St
Brooklyn ny 11211
(718)502-6969

$193.24

Get Your Coupon 26 more results found for pharmacy first

danny's pharmacy ii

110 W End Ave
New York ny 10023
(212)362-0000

$193.24

Get Your Coupon

north hudson community pharmacy

5301 Broadway
West New York nj 07093
(201)520-9364

$193.24

Get Your Coupon

139 center pharmacy, llc

139 Centre Street
New York ny 10013
(646)838-6388

$193.74

Get Your Coupon 219 more results found for leader drug stores inc

acme pharmacy #1083

125 18th St
Jersey City nj 07310
(201)418-0585

$195.25

Get Your Coupon 1 more results found for new albertsons lp

quick rx

909 Columbus Ave
New York ny 10025
(212)222-6388

$195.57

Get Your Coupon

103 pharmacy inc

2002 2nd Ave
New York ny 10029
(212)410-4410

$196.07

Get Your Coupon 33 more results found for health mart atlas 605

92 pharmacy

1938 2nd Ave
New York ny 10029
(212)426-6484

$196.07

Get Your Coupon 53 more results found for health mart atlas 630

a plus pharmacy

8 Baldwin Ave Ste B
Jersey City nj 07304
(201)451-4944

$196.07

Get Your Coupon 27 more results found for epic pharmacy network inc

echo care specialty pharmacy

260 Broadway
Brooklyn ny 11211
(718)782-3030

$196.07

Get Your Coupon

18 pharmacy inc

18 Elizabeth St
New York ny 10013
(212)571-0027

$196.16

Get Your Coupon 33 more results found for arete pharmacy network (783)

hudson pharmacy

65 08 Roosevelt Avenue
Woodside ny 11377
(347)448-6965

$196.16

Get Your Coupon

1699 fancy pharmacy inc

132 Allen St
New York ny 10002
(212)529-4532

$197.74

Get Your Coupon 80 more results found for elevate provider network 904

kmart pharmacy #7777

770 Broadway
New York ny 10003
(212)253-9661

$197.74

Get Your Coupon

care plus cvs/pharmacy #02546

1200 Harbor Blvd
Weehawken nj 07086
(201)330-8147

$198.24

Get Your Coupon 81 more results found for cvs pharmacy inc

cvs pharmacy #02919

126 Eighth Ave
New York ny 10011
(800)362-7828

$198.24

Get Your Coupon

cvs pharmacy #16969

139 Flatbush Ave
Brooklyn ny 11217
(718)290-1110

$198.24

Get Your Coupon 9 more results found for cvs pharmacy in target

walmart pharmacy 10-3520

400 Park Place
Secaucus nj 07094
(201)325-9275

$199.57

Get Your Coupon 1 more results found for walmart stores inc

apicha health center pharmacy

400 Broadway
New York ny 10013
(646)744-0994

$201.07

Get Your Coupon 4 more results found for maxorxpress

chelsea royal care pharmacy, inc.

154 9th Ave
New York ny 10011
(212)255-8000

$201.07

Get Your Coupon

chronos pharmacy

31 04 35th St
Astoria ny 11106
(718)932-8700

$201.07

Get Your Coupon

columbia drugs

55 Columbia St
New York ny 10002
(212)533-8120

$201.07

Get Your Coupon

contigo pharmacy

3510 Bergenline Ave
Union City nj 07087
(201)500-9366

$201.07

Get Your Coupon 6 more results found for gerimed ltc network inc

costco pharmacy #1062

517 E 117th St
New York ny 10035
(212)896-5882

$201.07

Get Your Coupon 1 more results found for costco pharmacies

pollock & bailey pharmacy

1032 1st Ave
New York ny 10022
(212)755-4244

$201.07

Get Your Coupon

rite aid pharmacy 01225

534 Hudson Street
New York ny 10014
(646)486-1048

$201.07

Get Your Coupon 32 more results found for rite aid corporation

ror madison pharmacy inc

1636 Madison Ave
New York ny 10029
(212)369-0700

$201.07

Get Your Coupon

rx center

2325 1st Ave
New York ny 10035
(212)289-8839

$201.07

Get Your Coupon

siri pharmacy inc

23 Flat Bush Ave
Brooklyn ny 11217
(718)596-7397

$201.07

Get Your Coupon

st johns pharmacy

2980 John F Kennedy Blvd
Jersey City nj 07306
(201)963-3617

$201.07

Get Your Coupon

titan pharmacy

3519 31st Ave
Astoria ny 11106
(718)267-8063

$201.07

Get Your Coupon

turtle bay chemists

901 2nd Ave
New York ny 10017
(212)752-5151

$201.07

Get Your Coupon

umr pharmacy & surgical inc

437 Central Ave
Jersey City nj 07307
(201)418-0009

$201.07

Get Your Coupon

united pharmacy

556 Grand St
Brooklyn ny 11211
(718)384-7901

$201.07

Get Your Coupon

community, a walgreens pharmacy #16463

29 W 116th St
New York ny 10026
(212)519-8346

$206.58

Get Your Coupon 126 more results found for walgreens drug store

Dosage and administration

DOSAGE AND ADMINISTRATION Dexamethasone sodium phosphate injection, 10 mg/mL– For intravenous and intramuscular injection only. Dexamethasone sodium phosphate injection can be given directly from the vial, or it can be added to Sodium Chloride Injection or Dextrose Injection and administered by intravenous drip. Solutions used for intravenous administration or further dilution of this product should be preservative free when used in the neonate, especially the premature infant. When it is mixed with an infusion solution, sterile precautions should be observed. Since infusion solutions generally do not contain preservatives, mixtures should be used within 24 hours. DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT. Intravenous and Intramuscular Injection The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated. In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required. The initial dosage should be maintained or adjusted until the patient’s response is satisfactory. If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy. After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response. Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily. If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually. When the intravenous route of administration is used, dosage usually should be the same as the oral dosage. In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. The slower rate of absorption by intramuscular administration should be recognized. Shock There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock. The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors: Author Dosage Cavanagh1 3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg Dietzman2 2 to 6 mg/kg of body weight as a single intravenous injection Frank3 40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists Oaks4 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists Schumer5 1 mg/kg of body weight as a single intravenous injection Administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours. Although adverse reactions associated with high dose, short-term corticosteroid therapy are uncommon, peptic ulceration may occur. Cerebral Edema Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside. Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with 2 mg two or three times a day may be effective. Acute Allergic Disorders In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone sodium phosphate injection, first day , 4 or 8 mg intramuscularly. Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day , 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit. This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit., Intravenous and Intramuscular Injection The initial dosage of dexamethasone sodium phosphate injection varies from 0.5 to 9 mg a day depending on the disease being treated. In less severe diseases doses lower than 0.5 mg may suffice, while in severe diseases doses higher than 9 mg may be required. The initial dosage should be maintained or adjusted until the patient’s response is satisfactory. If a satisfactory clinical response does not occur after a reasonable period of time, discontinue dexamethasone sodium phosphate injection and transfer the patient to other therapy. After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response. Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily. If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually. When the intravenous route of administration is used, dosage usually should be the same as the oral dosage. In certain overwhelming, acute, life-threatening situations, however, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. The slower rate of absorption by intramuscular administration should be recognized., Shock There is a tendency in current medical practice to use high (pharmacologic) doses of corticosteroids for the treatment of unresponsive shock. The following dosages of dexamethasone sodium phosphate injection have been suggested by various authors: Author Dosage Cavanagh1 3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg Dietzman2 2 to 6 mg/kg of body weight as a single intravenous injection Frank3 40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists Oaks4 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists Schumer5 1 mg/kg of body weight as a single intravenous injection Administration of high dose corticosteroid therapy should be continued only until the patient’s condition has stabilized and usually not longer than 48 to 72 hours. Although adverse reactions associated with high dose, short-term corticosteroid therapy are uncommon, peptic ulceration may occur., Cerebral Edema Dexamethasone sodium phosphate injection is generally administered initially in a dosage of 10 mg intravenously followed by four mg every six hours intramuscularly until the symptoms of cerebral edema subside. Response is usually noted within 12 to 24 hours and dosage may be reduced after two to four days and gradually discontinued over a period of five to seven days. For palliative management of patients with recurrent or inoperable brain tumors, maintenance therapy with 2 mg two or three times a day may be effective., and Acute Allergic Disorders In acute, self-limited allergic disorders or acute exacerbations of chronic allergic disorders, the following dosage schedule combining parenteral and oral therapy is suggested: Dexamethasone sodium phosphate injection, first day , 4 or 8 mg intramuscularly. Dexamethasone tablets, 0.75 mg: second and third days, 4 tablets in two divided doses each day; fourth day , 2 tablets in two divided doses; fifth and sixth days, 1 tablet each day; seventh day, no treatment; eighth day, follow-up visit. This schedule is designed to ensure adequate therapy during acute episodes, while minimizing the risk of overdosage in chronic cases. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever the solution and container permit.

Author Dosage
Cavanagh1 3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg
Dietzman2 2 to 6 mg/kg of body weight as a single intravenous injection
Frank3 40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists
Oaks4 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists
Schumer5 1 mg/kg of body weight as a single intravenous injection
and
Author Dosage
Cavanagh1 3 mg/kg of body weight per 24 hours by constant intravenous infusion after an initial intravenous injection of 20 mg
Dietzman2 2 to 6 mg/kg of body weight as a single intravenous injection
Frank3 40 mg initially followed by repeat intravenous injection every 4 to 6 hours while shock persists
Oaks4 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists
Schumer5 1 mg/kg of body weight as a single intravenous injection

Indications And Usage

INDICATIONS AND USAGE By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy.

Overdosage

OVERDOSAGE Reports of acute toxicity and/or death following overdosage of glucocorticoids are rare. In the event of overdosage, no specific antidote is available; treatment is supportive and symptomatic. The oral LD50 of dexamethasone in female mice was 6.5 g/kg. The intravenous LD50 of dexamethasone sodium phosphate in female mice was 794 mg/kg.

Adverse Reactions

ADVERSE REACTIONS Fluid and electrolyte disturbances: Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal: Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Tendon rupture Pathologic fracture of long bones Gastrointestinal: Peptic ulcer with possible subsequent perforation and hemorrhage Perforation of the small and large bowel; particularly in patients with inflammatory bowel disease Pancreatitis Abdominal distention Ulcerative esophagitis Dermatologic: Impaired wound healing Thin fragile skin Petechiae and ecchymoses Erythema Increased sweating May suppress reactions to skin tests Burning or tingling, especially in the perineal area (after IV injection) Other cutaneous reactions, such as allergic dermatitis, urticaria, angioneurotic edema Neurologic: Convulsions Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Vertigo Headache Psychic disturbances Endocrine: Menstrual irregularities Development of cushingoid state Suppression of growth in pediatric patients Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Hirsutism Ophthalmic: Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos Retinopathy of prematurity Metabolic: Negative nitrogen balance due to protein catabolism Cardiovascular: Myocardial rupture following recent myocardial infarction (see WARNINGS ) Hypertrophic cardiomyopathy in low birth weight infants Other: Anaphylactoid or hypersensitivity reactions Thromboembolism Weight gain Increased appetite Nausea Malaise Hiccups The following additional adverse reactions are related to parenteral corticosteroid therapy: Hyperpigmentation or hypopigmentation Subcutaneous and cutaneous atrophy Sterile abscess Charcot-like arthropathy

Contraindications

CONTRAINDICATIONS Systemic fungal infections (see WARNINGS regarding amphotericin B). Hypersensitivity to any component of this product (see WARNINGS ) .